SavedAdd your journal

Journals / Anadolu Kardiyoloji Dergisi / 2013 / Cilt: 13 - Sayı: 2

Behçet hastalığında nebivololün endotel disfonksiyonuna etkisi; prospektif, tek grup kontrollü çalışma

Effect of nebivolol on endothelial dysfunction in patients with Behçet’s disease; a prospective single-arm controlled study

Abdurrahman OĞUZHAN
Murat BORLU
Ömer ŞAHİN
Hasan AKKAYA
Mustafa Serkan KARAKAŞ
Pages
115–120
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: A significant improvement was observed in FMD after therapy period (4.23±1.19 vs 7.95±2.21%, p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Behçet’s disease (BD) is a systemic vasculitis, capable of involving all types of vessels.
📊
Key Findings & Data:We prospectively studied 35 Behçet’s patients who were diag- nosed according to the International Study Group criteria.
💡
Conclusion & Impact:Results: A significant improvement was observed in FMD after therapy period (4.23±1.19 vs 7.95±2.21%, p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Behçet’s disease (BD) is a systemic vasculitis, capable of involving all types of vessels. Endothelial dysfunction (ED) has been previ- ously documented in BD. Previous studies showed that nebivolol might improve endothelial functions in endothelial dysfunction. The aim of our study is to assess the effects of nebivolol on endothelial dysfunction in patients with Behçet’s disease. Methods: This study was designed as prospective single-arm controlled study. We prospectively studied 35 Behçet’s patients who were diag- nosed according to the International Study Group criteria. Patients received 5 mg nebivolol per day for 3 months. Endothelial dysfunction was evaluated by brachial artery flow-mediated dilatation (FMD) method using high-resolution vascular ultrasound device at baseline and after for 3-month therapy. The paired samples t test, Wilcoxon test, Pearson, Spearman correlation analyses were used for statistical analysis. Results: A significant improvement was observed in FMD after therapy period (4.23±1.19 vs 7.95±2.21%, p

Özet

Amaç: Behçet Hastalığı (BH) tüm damarları tutabilen sistemik bir vaskülittir. BH’da endotel disfonksiyonu geliştiği gösterilmiştir. Daha önce yapılan çalışmalarda nebivololün endotel disfonksiyonunda endotel fonksiyonlarını iyileştirdiği gösterilmiştir. Çalışmamızın amacı BH’da nebivo- lolün endotel disfonksiyonu üzerine etkisini araştırmaktır. Yöntemler: Bu araştırma prospektif, tek grup kontrollü çalışma olarak tasarlandı. Çalışmaya Uluslararası Çalışma Grubu kriterlerine uyan 35 BH alındı. Hastalara 3 ay süreyle 5 mg/gün nebivolol verildi. Endotel disfonksiyonu, çalışmanın başlangıcında ve 3 ay tedavi sonrası yüksek çözü- nürlüklü vasküler ultrason cihazı kullanılarak brakiyal arter akım aracılı dilatasyon metodu ile değerlendirildi. Paired samples t test, Wilcoxon test, Pearson, Spearmann korelasyon analizleri istatistiksel değerlendirme için kullanıldı. Bulgular: Tedavi sonrasında akım aracılı dilatasyonda belirgin iyileşme izlendi (4.23±1.19 vs 7.95±2.21%, p

🔖

Cite This Article

OĞUZHAN, A., BORLU, M., ŞAHİN, Ö., AKKAYA, H., KARAKAŞ, M. S. (2022). Behçet hastalığında nebivololün endotel disfonksiyonuna etkisi; prospektif, tek grup kontrollü çalışma. Anadolu Kardiyoloji Dergisi, Cilt: 13 - Sayı: 2, 115–120. https://ajindex.com/articles/436295

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (5)

  1. Koç Y, Güllü I, Akpek G, Akpolat T, Kansu E, Kiraz S, et al. Vascular involvement in Behçet’s disease. J Rheumatol 1992; 19: 402-10
  2. Ehrlich GE. Vasculitis in Behçet’s disease. Int Rev Immunol 1997; 14: 81-8. [CrossRef] 3. Oflaz H, Mercanoğlu F, Karaman O, Kamalı S, Erer B, Gençhellaç H, et al. Impaired endothelium-dependent flow-mediated dilatation in Behçet’s disease: more prominent endothelial dysfunction in patients with vascular involvement. Int J Clin Pract 2005; 59: 777-81. [CrossRef] 4. Evereklioğlu C. Current concepts in the etiology and treatment of Behçet disease. Surv Ophthalmol 2005; 50: 297-350. [CrossRef] 5. Düzgün N, Ayaşlıoğlu E, Tutkak H, Şahin M, Aydıntuğ O, Ölmez U. Plasma trombomodulin levels in patients with Behçet’s disease. Rheumatol Int 2003; 23: 130-3
  3. Haznedaroğlu İC, Özcebe Oİ, Özdemir O, Çelik İ, Dündar SV, Kirazlı Ş. Impaired haemostatic kinetics and endothelial function in Behçet’s disease. J Intern Med 1996; 240: 181-7. [CrossRef] 7. Güllü H, Çalışkan M, Erdoğan D, Yılmaz S, Dursun R, Çiftçi Ö, et al. Patients with Behçet’s disease carry a higher risk for microvascular involvement in active disease period. Ann Med 2007; 39: 154-9. [CrossRef] 8. Mege JL, Dilsen N, Sanguedolce V, Gül A, Bongrand P Roux H, et al. Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behçet’s disease. A comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol 1993; 20: 1544-9
  4. Niwa Y, Miyake S, Sakane T, Shingu M, Yokoyama M. Auto- oxidative damage in Behçet’s disease-endothelial cell damage following the elevated oxygen radicals generated by stimulated neutrophils. Clin Exp Immunol 1982; 49: 247-55
  5. Chambers JC, Haskard DO, Kooner JS. Vascular endothelial function and oxidative stress mechanisms in patients with Behçet’s syndrome. J Am Coll Cardiol 2001; 37: 517-20. [CrossRef] 11. Buldanlıoğlu S, Türkmen S, Ayabakan HB, Yenice N, Vardar M, Doğan S, et al. Nitric oxide, lipid peroxidation and antioxidant defense system in patients with active or inactive Behçet’s disease. Br J Dermatol 2005; 153: 526-30. [CrossRef] 12. Hızlı N, Şahin G, Şahin F, Kansu E, Duru S, Karacadağ S, et al. Plasma prostacyclin levels in Behçet’s disease. Lancet 1985; 1: 1454. [CrossRef] 13. Cockcroft JR, Chowienczyk PJ, Brett SE, Chen CP Dupont AG, Van Nueten L, et al. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine